Twenty-Four-Week UACR Response Trajectories and Clinical Correlates of Residual Albuminuria in Diabetic Kidney Disease During Finerenone Therapy: A Real-World Longitudinal Study
Yang Zhang, Qin Zhu, Chaochao Wang, Xiaoqiao Cai, Shengfen Lin, Beibei Ding, Xingyu Zhu, Yongqiang Lin · 2026
Read Twenty-Four-Week UACR Response Trajectories and Clinical Correlates of Residual Albuminuria in Diabetic Kidney Disease During Finerenone Therapy: A Real-World Longitudinal Study by Yang Zhang, Qin Zhu, Chaochao Wang, Xiaoqiao Cai, Shengfen Lin, Beibei Ding, Xingyu Zhu, Yongqiang Lin (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13594514.txt.
Description
Yang Zhang and co-authors track how protein leakage from the kidneys evolves during a new diabetes drug's first months, in a 2026 study. Finerenone protects diabetic kidneys, but some patients keep leaking albumin into urine despite treatment. A single before-and-after reading can hide very different paths. The team studied 136 patients at one centre who still leaked protein after at least four weeks on the drug.
Urine measurements over twenty-four weeks were sorted into response patterns by a statistical model that finds hidden groups. Three paths emerged, from favourable response to stubborn leakage. The team then asked which clinical features marked the patients whose leakage persisted. The results help doctors spot early who needs extra treatment beyond the drug, instead of waiting months to find out.
Catalog record
| CREATOR | Yang Zhang, Qin Zhu, Chaochao Wang, Xiaoqiao Cai, Shengfen Lin, Beibei Ding, Xingyu Zhu, Yongqiang Lin |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |